Across TCGA pan-cancer cohorts, TRDV2 RNA differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of TRDV2’s most consistent transcriptional readouts.

The strongest signal is observed in breast invasive carcinoma (BRCA), where TRDV2 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types TRDV2 is over-expressed in tumor, although a few such as LUAD and STAD show the opposite, repressed pattern.

BRCA, HNSC, and LUAD are the cancer types where TRDV2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in TRDV2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BRCA	All	All	+0.092	.002	4	view →
HNSC	Female	II,III,IV	+0.046	.022	4	view →
LUAD	Male	All	−0.085	.036	2	view →
STAD	Male	II,III,IV	−0.084	.020	2	view →
KIRC	All	All	+0.062	.002	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: TRDV2 RNA expression & survival · all TRDV2 data types